Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | GNRHR | P30968 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3047191 | 0.90 | HDAC1 (0.45) | HDAC1SLC2A1HTTPOLB | |
| Trifluoroacetic Acid SCHEMBL3037461 | 0.84 | S1PR2 (0.38) | SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL3051308 | 0.83 | HTR5A (0.44) | HDAC1 | |
| Trifluoroacetic Acid SCHEMBL3051554 | 0.82 | KDM4E (0.47) | HDAC1SLC2A1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3050294 | 0.81 | HDAC6 (0.42) | HDAC1SLC2A1POLB | |
| Trifluoroacetic Acid SCHEMBL3041965 | 0.81 | HDAC1 (0.47) | HDAC1 | |
| Trifluoroacetic Acid SCHEMBL3039719 | 0.80 | MEN1 (0.43) | HDAC1SLC2A1POLBPRKD1 | |
| Trifluoroacetic Acid SCHEMBL3048936 | 0.80 | HDAC1 (0.37) | HDAC1SLC2A1DYRK1A | |
| SCHEMBL13136956 | 0.80 | QPCT (0.48) | HDAC1HTTPOLB | |
| Trifluoroacetic Acid SCHEMBL3046203 | 0.79 | HTR5A (0.46) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HDAC1 2221/4885SLC2A1 4262/4885ALDH1A1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.